Edition:
United Kingdom

T2 Biosystems Inc (TTOO.OQ)

TTOO.OQ on NASDAQ Stock Exchange Global Market

3.54USD
18 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.54
Open
$3.60
Day's High
$3.66
Day's Low
$3.49
Volume
66,456
Avg. Vol
122,281
52-wk High
$9.98
52-wk Low
$3.49

Latest Key Developments (Source: Significant Developments)

T2 Biosystems Announces Pricing Of Public Offering Of Common Stock
Thursday, 31 May 2018 

May 31 (Reuters) - T2 Biosystems Inc ::T2 BIOSYSTEMS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.T2 BIOSYSTEMS - PRICING OF UNDERWRITTEN REGISTERED PUBLIC OFFERING OF 6.1 MILLION SHARES OF COMMON STOCK AT $7.50 PER SHARE.  Full Article

T2 Biosystems Reports Q1 Loss Per Share Of $0.36
Tuesday, 8 May 2018 

May 8 (Reuters) - T2 Biosystems Inc ::T2 BIOSYSTEMS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.QTRLY LOSS PER SHARE $0.36.SEES Q2 2018 REVENUE $3.0 MILLION TO $3.3 MILLION.Q1 REVENUE ROSE 146 PERCENT TO $2.311 MILLION.Q1 REVENUE VIEW $1.4 MILLION -- THOMSON REUTERS I/B/E/S.TOTAL REVENUE IN Q2 2018 IS EXPECTED TO BE IN RANGE OF $3.0 MILLION TO $3.3 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S .  Full Article

T2 Biosystems Says ‍Total Q4 Revenue Is Expected To Exceed Previously Guided Range Of $1.1 Mln To $1.3 Mln​
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - T2 Biosystems Inc ::T2 BIOSYSTEMS ANNOUNCES PRELIMINARY FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON T2BACTERIA PANEL.- ‍FDA CLEARANCE OF T2BACTERIA PANEL REMAINS ON TRACK FOR Q1 2018​.‍TOTAL REVENUE IN Q4 IS EXPECTED TO EXCEED PREVIOUSLY GUIDED RANGE OF $1.1 TO $1.3 MILLION​.  Full Article

T2 Biosystems Q3 loss per share $0.45
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - T2 Biosystems Inc :T2 biosystems reports third quarter 2017 financial results and provides company update.Q3 loss per share $0.45.Sees q4 revenue $1.1 million to $1.3 million.Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S.Q3 revenue $1.1 million versus i/b/e/s view $1.1 million.T2 biosystems inc - ‍company reaffirms expectations regarding timeframe for fda clearance of t2bacteria panel​.T2 biosystems inc - ‍continues to prepare for commercial launch of t2bacteria panel in u.s. As early as year-end, pending market clearance by fda.​.T2 biosystems inc - ‍cash and cash equivalents as of sept 30 with additional remaining liquidity on term loan , should extend cash runway into h1 2019​.  Full Article